Cialis 40 mg

Aktīvā viela: Tadalafil 40mg per tablet

Therapeutic Class: Phosphodiesterase type 5 (PDE5) inhibitor

Description:
Cialis 40mg is a high-dose formulation of tadalafil, a potent and selective PDE5 inhibitor. This dosage is specifically designed for men requiring stronger treatment for erectile dysfunction (ED). The 40mg strength offers enhanced efficacy while maintaining tadalafil’s characteristic 36-hour duration of action.

Indikācijas:

• Treatment of erectile dysfunction in adult men

• Management of benign prostatic hyperplasia (BPH) symptoms

• Combined treatment of ED and BPH (when clinically indicated)

Devas un ievadīšana:

• Recommended starting dose: 10mg or 20mg (40mg reserved for special cases)

• Maximum recommended frequency: Once daily

• Administration: Take orally with water, at least 30 minutes before anticipated sexual activity

• May be taken with or without food (avoid high-fat meals)

• Not for use in women or pediatric populations

Pharmacokinetics:

• Time to peak plasma concentration: 2 hours (range 0.5-6 hours)

• Terminal half-life: 17.5 hours

• Duration of effect: Up to 36 hours

• Protein binding: Approximately 94%

Clinical Advantages:

• Extended therapeutic window allows for more spontaneous sexual activity

• Demonstrated efficacy in men with diabetes mellitus

• Effective in difficult-to-treat ED cases

• Maintains efficacy with alcohol consumption (within moderate limits)

Safety Information:
[Black Box Warning]
CONTRAINDICATED WITH NITRATES – Concomitant use with organic nitrates in any form is strictly prohibited due to risk of life-threatening hypotension.

Common Adverse Reactions (≥2%):

• Headache (15%)

• Dyspepsia (10%)

• Back pain (6%)

• Myalgia (5%)

• Nasal congestion (4%)

• Flushing (3%)

• Limb pain (3%)

Serious Adverse Reactions:

• Priapism (prolonged erection >4 hours)

• Sudden hearing loss

• Non-arteritic anterior ischemic optic neuropathy (NAION)

• Cardiovascular events in predisposed patients

Drug Interactions:

• Absolute contraindication with nitrates

• Caution with alpha-blockers (risk of hypotension)

• Moderate CYP3A4 inhibitors may increase tadalafil exposure

• Rifampin significantly decreases tadalafil exposure

Special Populations:

• Renal impairment: Not recommended in severe cases (CrCl <30 mL/min)

• Hepatic impairment: Maximum 10mg dose in moderate-severe cases

• Elderly: Consider lower starting dose

• CYP3A4 inducers: May require dose adjustment

Storage Conditions:

• Store below 30°C (86°F)

• Protect from moisture and light

• Keep in original packaging until use

Packaging Options:

• 1 tablet blister pack (sample)

• 4 tablet treatment pack

• 8 tablet value pack

Legal Status:
Prescription-only medication (Schedule H/Schedule IV depending on country)

Manufacturer:
[Insert Pharmaceutical Company Information]

Prescribing Considerations:

• Complete cardiovascular assessment recommended prior to prescription

• Individualize dosage based on patient needs and tolerability

• Consider lower starting dose in elderly or patients with comorbidities

• Counsel patients on proper use and potential adverse effects

Patient Counseling Information:

• Explain proper dosing and administration

• Review contraindications and warnings

• Discuss what to do if adverse effects occur

• Emphasize that sexual stimulation is required for effect

• Advise to seek immediate medical attention for erections >4 hours